Actos Patent Expiry Fuels Takeda's Drive For Deals - Licensing Exec
This article was originally published in PharmAsia News
Executive Summary
Takeda is looking to partner with companies owning late-stage compounds in an effort to replace revenue that will likely be lost following U.S. patent expiry of its blockbuster type 2 diabetes treatment Actos (pioglitazone), according to General Manager of Global Licensing & Business Development Hiroaki Ogata
You may also be interested in...
Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.
Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
Japanese firm simultaneously announces that it has inked a monoclonal antibody discovery deal with Xoma.
Generic Firms Must Pay Actos Legal Fees, Partly Because Of Claim Flip-Flops
In deciding for Takeda, judge says Mylan and Alphapharm also disregarded court orders and used faulty witnesses during their patent challenges.